JP2007532607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532607A5 JP2007532607A5 JP2007507771A JP2007507771A JP2007532607A5 JP 2007532607 A5 JP2007532607 A5 JP 2007532607A5 JP 2007507771 A JP2007507771 A JP 2007507771A JP 2007507771 A JP2007507771 A JP 2007507771A JP 2007532607 A5 JP2007532607 A5 JP 2007532607A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lower alkyl
- composition according
- unsubstituted
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 46
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- -1 methylpyrrolyl Chemical group 0.000 claims 7
- 206010019233 Headaches Diseases 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 231100000869 headache Toxicity 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- XCVDGQBGMARFRY-GFCCVEGCSA-N (2r)-2-acetamido-n-[(3-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC(F)=C1 XCVDGQBGMARFRY-GFCCVEGCSA-N 0.000 claims 1
- PVNGTPGYSFGJIH-GFCCVEGCSA-N (2r)-2-acetamido-n-[(4-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=C(F)C=C1 PVNGTPGYSFGJIH-GFCCVEGCSA-N 0.000 claims 1
- SGBCQENKTXKIRD-MRXNPFEDSA-N (2r)-2-acetamido-n-benzyl-2-phenylacetamide Chemical compound O=C([C@H](NC(=O)C)C=1C=CC=CC=1)NCC1=CC=CC=C1 SGBCQENKTXKIRD-MRXNPFEDSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56268104P | 2004-04-16 | 2004-04-16 | |
| PCT/EP2005/004047 WO2005099740A1 (en) | 2004-04-16 | 2005-04-15 | Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532607A JP2007532607A (ja) | 2007-11-15 |
| JP2007532607A5 true JP2007532607A5 (enExample) | 2008-04-17 |
Family
ID=34963770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507771A Pending JP2007532607A (ja) | 2004-04-16 | 2005-04-15 | 慢性頭痛の予防及び治療のためのペプチド化合物の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8008351B2 (enExample) |
| EP (1) | EP1734980A1 (enExample) |
| JP (1) | JP2007532607A (enExample) |
| KR (1) | KR20070007931A (enExample) |
| CN (1) | CN1950101B (enExample) |
| AU (1) | AU2005232395B2 (enExample) |
| BR (1) | BRPI0509903A (enExample) |
| CA (1) | CA2562937A1 (enExample) |
| EA (1) | EA013591B1 (enExample) |
| IL (1) | IL178442A0 (enExample) |
| MX (1) | MXPA06011937A (enExample) |
| NO (1) | NO20065251L (enExample) |
| NZ (1) | NZ550482A (enExample) |
| WO (1) | WO2005099740A1 (enExample) |
| ZA (1) | ZA200608241B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE327744T1 (de) | 2001-03-20 | 2006-06-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz |
| DE60100055T2 (de) | 2001-03-21 | 2003-07-24 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| BRPI0417101A (pt) | 2003-12-02 | 2007-02-06 | Sanol Arznei Schwarz Gmbh | uso de compostos de peptìdeo para tratamento de dor neuropática central |
| EP1579858A1 (en) * | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| MX2007002269A (es) | 2004-08-27 | 2007-06-15 | Sanol Arznei Schwarz Gmbh | Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos. |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US7902401B2 (en) | 2006-12-14 | 2011-03-08 | Nps Pharmaceuticals, Inc. | Fluorinated compounds |
| KR20090018863A (ko) * | 2006-06-08 | 2009-02-23 | 쉬바르츠파르마에이지 | 통증성 의학적 상태를 위한 치료제 조합 |
| KR20150003925A (ko) | 2006-06-15 | 2015-01-09 | 유씨비 파르마 게엠베하 | 상승적 항경련 효과를 갖는 약제학적 조성물 |
| CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| EP2099444A4 (en) | 2006-12-14 | 2012-11-07 | Nps Pharma Inc | USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES |
| US8609810B2 (en) * | 2009-05-29 | 2013-12-17 | Ruprecht-Karls-Universitat Heidelberg | Methylglyoxal-scavenging compounds and their use for the prevention and treatment of pain and/or hyperalgesia |
| CA2774569A1 (en) | 2009-09-23 | 2011-03-31 | The University Of North Carolina At Chapel Hill | Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
| US20130251813A1 (en) | 2010-12-02 | 2013-09-26 | Ucb Pharma Gmbh | Formulation of lacosamide |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2937698A1 (de) | 1979-09-18 | 1981-04-02 | A. Nattermann & Cie GmbH, 5000 Köln | N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4533657A (en) | 1981-07-24 | 1985-08-06 | Sterling Drug Inc. | Analgesic dipeptide amides and method of use and composition thereof |
| FR2518088B1 (fr) | 1981-12-16 | 1987-11-27 | Roques Bernard | Nouveaux derives d'aminoacides, et leur application therapeutique |
| US4510082A (en) | 1983-03-07 | 1985-04-09 | Eli Lilly And Company | Pharmacologically active peptides |
| JPH0680079B2 (ja) | 1984-11-09 | 1994-10-12 | エーザイ株式会社 | ポリペプチド |
| US5378729A (en) | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5654301A (en) * | 1985-02-15 | 1997-08-05 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| GB9103454D0 (en) | 1991-02-19 | 1991-04-03 | Pfizer Ltd | Therapeutic agents |
| US5656267A (en) | 1991-08-22 | 1997-08-12 | Sagen; Jacqueline | Implantable cells that alleviate chronic pain in humans |
| TW217417B (enExample) | 1991-12-04 | 1993-12-11 | Manyu Seiyaku Kk | |
| US5585358A (en) * | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| GB9504854D0 (en) | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| US5536853A (en) | 1994-04-11 | 1996-07-16 | Chiron Corporation | Opiate receptor ligands |
| MY113062A (en) | 1994-05-10 | 2001-11-30 | The Wellcome Foundation Ltd | Amide derivatives and their therapeutic use |
| US5508266A (en) | 1994-06-22 | 1996-04-16 | Ciba-Geigy Corporation | Gem-disubstituted amino acid derivatives |
| FI971412A7 (fi) | 1994-10-05 | 1997-04-04 | Darwin Discovery Ltd | Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| US5780589A (en) | 1994-11-30 | 1998-07-14 | The United States Of America As Represented By The Department Of Health And Human Services | Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof |
| US5760038A (en) | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5849737A (en) | 1995-04-14 | 1998-12-15 | The Regents Of The University Of California | Compositions and methods for treating pain |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US6114390A (en) | 1995-11-30 | 2000-09-05 | Karl Thomae Gmbh | Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| GB9601724D0 (en) | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| DE19614533A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
| DE19614534A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19614542A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| US6277825B1 (en) | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| US6589994B1 (en) | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| DE19636046A1 (de) | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
| US6048899A (en) * | 1997-03-17 | 2000-04-11 | Research Corporation Tech., Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| US5866585A (en) | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| ATE320249T1 (de) | 1997-07-08 | 2006-04-15 | Ono Pharmaceutical Co | Aminosäurederivate |
| ATE225171T1 (de) * | 1997-07-15 | 2002-10-15 | Res Corp Technologies Inc | Aminosäurederivate zur behandlung von schlaganfall |
| US6737408B1 (en) | 1997-08-07 | 2004-05-18 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| AU7696098A (en) | 1997-08-11 | 1999-03-01 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
| DE19743143A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| ID24278A (id) | 1997-10-31 | 2000-07-13 | Basf Ag | Turunan-turunan asam karboksilat baru dengan rantai sisi amida, pembuatan dan penggunaannya sebagai reseptor antagonis endotelin |
| US6028102A (en) | 1998-02-24 | 2000-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticonvulsant drugs and pharmaceutical compositions thereof |
| CA2361402C (en) | 1999-09-03 | 2009-05-12 | Actelion Pharmaceuticals Ltd | Bis-sulfonamides |
| SE0001373D0 (sv) | 2000-04-13 | 2000-04-13 | Karolinska Innovations Ab | NPY Y1 receptor agonists and antagonists |
| SI1311256T1 (sl) * | 2000-08-17 | 2005-12-31 | Teva Pharma | Uporaba derivatov amidov valprojske kisline in amidov 2-valproenske kisline za zdravljenje ali preprecevanje bolecin in/ali glavobolnih motenj |
| ES2435000T3 (es) * | 2000-08-25 | 2013-12-18 | Research Corporation Technologies, Inc. | Aminoácidos anticonvulsionantes para el tratamiento del dolor |
| WO2002042256A2 (en) | 2000-11-21 | 2002-05-30 | Ucb, S.A. | N-alkylated gaba compounds, processes for their preparation and their use as medicaments |
| ATE327744T1 (de) * | 2001-03-20 | 2006-06-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz |
| DE60100055T2 (de) * | 2001-03-21 | 2003-07-24 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| WO2004060352A1 (en) | 2002-12-19 | 2004-07-22 | Pharmacia Corporation | Non-hygroscopic formulation comprising a hydroscopic drug |
| US7320675B2 (en) | 2003-08-21 | 2008-01-22 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
| EP1537862A1 (en) | 2003-12-02 | 2005-06-08 | Schwarz Pharma Ag | Novel use of peptide compounds for treating central neuropathic pain |
| BRPI0417101A (pt) * | 2003-12-02 | 2007-02-06 | Sanol Arznei Schwarz Gmbh | uso de compostos de peptìdeo para tratamento de dor neuropática central |
| EP1541138A1 (en) | 2003-12-05 | 2005-06-15 | Schwarz Pharma Ag | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20060009384A1 (en) * | 2003-12-05 | 2006-01-12 | David Rudd | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| EP1579858A1 (en) | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| US20050227961A1 (en) | 2004-04-08 | 2005-10-13 | Vela Pharmaceuticals, Inc. | Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome |
| EP1604654A1 (en) * | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| MX2007002269A (es) | 2004-08-27 | 2007-06-15 | Sanol Arznei Schwarz Gmbh | Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos. |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| EP1688137A1 (en) | 2005-01-28 | 2006-08-09 | Schwarz Pharma Ag | SPM 927 for add-on therapy of schizophrenia |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| KR20150003925A (ko) * | 2006-06-15 | 2015-01-09 | 유씨비 파르마 게엠베하 | 상승적 항경련 효과를 갖는 약제학적 조성물 |
| WO2009053070A1 (en) * | 2007-10-23 | 2009-04-30 | Schwarz Pharma Ag | Compounds for treating demyelination conditions |
-
2005
- 2005-04-15 CN CN200580014652XA patent/CN1950101B/zh not_active Expired - Fee Related
- 2005-04-15 EP EP05729930A patent/EP1734980A1/en not_active Withdrawn
- 2005-04-15 JP JP2007507771A patent/JP2007532607A/ja active Pending
- 2005-04-15 US US10/599,976 patent/US8008351B2/en not_active Expired - Fee Related
- 2005-04-15 NZ NZ550482A patent/NZ550482A/en unknown
- 2005-04-15 EA EA200601912A patent/EA013591B1/ru not_active IP Right Cessation
- 2005-04-15 AU AU2005232395A patent/AU2005232395B2/en not_active Expired - Fee Related
- 2005-04-15 WO PCT/EP2005/004047 patent/WO2005099740A1/en not_active Ceased
- 2005-04-15 BR BRPI0509903-0A patent/BRPI0509903A/pt not_active Application Discontinuation
- 2005-04-15 KR KR1020067023956A patent/KR20070007931A/ko not_active Ceased
- 2005-04-15 CA CA002562937A patent/CA2562937A1/en not_active Abandoned
- 2005-04-15 MX MXPA06011937A patent/MXPA06011937A/es not_active Application Discontinuation
-
2006
- 2006-10-04 ZA ZA200608241A patent/ZA200608241B/en unknown
- 2006-10-04 IL IL178442A patent/IL178442A0/en unknown
- 2006-11-15 NO NO20065251A patent/NO20065251L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532607A5 (enExample) | ||
| JP2008501753A5 (enExample) | ||
| JP2008501760A5 (enExample) | ||
| JP2007530493A5 (enExample) | ||
| JP2008503533A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| JP2015528471A5 (enExample) | ||
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| JP2014515373A5 (enExample) | ||
| JP2004519469A5 (enExample) | ||
| JP2015503540A5 (enExample) | ||
| MXPA05003366A (es) | Inhibidores de la proteina reguladora de conductancia transmembranal de la fibrosis quistica y usos de los mismos. | |
| JP2014516942A5 (enExample) | ||
| JP2016517431A5 (enExample) | ||
| JP2012515184A5 (enExample) | ||
| NZ604983A (en) | Dry powder formulation comprising an antimuscarinic drug | |
| JP2019517587A5 (enExample) | ||
| JP2002519425A5 (enExample) | ||
| JP2010540519A5 (enExample) | ||
| JP2009532438A5 (enExample) | ||
| JP2009513713A5 (enExample) | ||
| JP2010514834A5 (enExample) | ||
| JP2008540506A5 (enExample) | ||
| JP2012504584A5 (enExample) |